1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA
Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04
Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule
Reports Second Quarter 2025 Financial Results and Provides Business Update
News, Underwriting Agreement, Legal Opinion
News, Articles of Incorporation, Material Contracts
Other Events
Announces Pricing of $3.6 Million Public Offering
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Amended Registration Statement for Securities
Prospectus filed pursuant to Rule 424(b)(3)
PRER14A
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Definitive Revised Proxy Statement
Correspondence
Submission Upload